These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12933583)

  • 1. Selective targeted delivery of TNFalpha to tumor blood vessels.
    Borsi L; Balza E; Carnemolla B; Sassi F; Castellani P; Berndt A; Kosmehl H; Biro A; Siri A; Orecchia P; Grassi J; Neri D; Zardi L
    Blood; 2003 Dec; 102(13):4384-92. PubMed ID: 12933583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.
    Balza E; Mortara L; Sassi F; Monteghirfo S; Carnemolla B; Castellani P; Neri D; Accolla RS; Zardi L; Borsi L
    Clin Cancer Res; 2006 Apr; 12(8):2575-82. PubMed ID: 16638868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.
    Crescenzi M; Persano L; Esposito G; Zulato E; Borsi L; Balza E; Ruol A; Ancona E; Indraccolo S; Amadori A
    Clin Cancer Res; 2011 Feb; 17(3):447-58. PubMed ID: 21106730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.
    Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L
    Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
    Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
    Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
    Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Kaspar M; Trachsel E; Neri D
    Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.
    Balza E; Carnemolla B; Mortara L; Castellani P; Soncini D; Accolla RS; Borsi L
    Int J Cancer; 2010 Jul; 127(1):101-10. PubMed ID: 19877124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
    Demartis S; Tarli L; Borsi L; Zardi L; Neri D
    Eur J Nucl Med; 2001 Apr; 28(4):534-9. PubMed ID: 11357506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.
    Borsi L; Balza E; Bestagno M; Castellani P; Carnemolla B; Biro A; Leprini A; Sepulveda J; Burrone O; Neri D; Zardi L
    Int J Cancer; 2002 Nov; 102(1):75-85. PubMed ID: 12353237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.
    Ventura E; Balza E; Borsi L; Tutolo G; Carnemolla B; Castellani P; Zardi L
    BMC Biotechnol; 2011 Nov; 11():104. PubMed ID: 22074550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides.
    Niesner U; Halin C; Lozzi L; Günthert M; Neri P; Wunderli-Allenspach H; Zardi L; Neri D
    Bioconjug Chem; 2002; 13(4):729-36. PubMed ID: 12121127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.
    Nilsson F; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2001 Jan; 61(2):711-6. PubMed ID: 11212273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.
    Berndorff D; Borkowski S; Moosmayer D; Viti F; Müller-Tiemann B; Sieger S; Friebe M; Hilger CS; Zardi L; Neri D; Dinkelborg LM
    J Nucl Med; 2006 Oct; 47(10):1707-16. PubMed ID: 17015908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-affinity human antibody that targets tumoral blood vessels.
    Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L
    Blood; 1999 Jul; 94(1):192-8. PubMed ID: 10381513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.
    Ebbinghaus C; Ronca R; Kaspar M; Grabulovski D; Berndt A; Kosmehl H; Zardi L; Neri D
    Int J Cancer; 2005 Aug; 116(2):304-13. PubMed ID: 15800913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
    Lu L; Li ZJ; Li LF; Shen J; Zhang L; Li MX; Xiao ZG; Wang JH; Cho CH
    Peptides; 2017 Nov; 97():54-63. PubMed ID: 28970092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Cancer Therapy Using Fusion Protein of TNFα and Tumor-Associated Fibronectin-Specific Aptide.
    Jeon H; Kim D; Choi M; Kang S; Kim JY; Kim S; Jon S
    Mol Pharm; 2017 Nov; 14(11):3772-3779. PubMed ID: 28969419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.